SCHEMBL2202998

SCHEMBL2202998

Cc1c(-c2cccc(Br)c2)nn(C)c1C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 3/20 0.40
KMT2A Q03164 3/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
LMNA P02545 2/20 0.40
CNR1 P21554 2/20 0.40
GPR55 Q9Y2T6 2/20 0.40
CNR2 P34972 1/20 0.40
HTT P42858 1/20 0.40
PLAU P00749 1/20 0.40
MEN1 O00255 2/20 0.39
RXFP1 Q9HBX9 2/20 0.39
NPSR1 Q6W5P4 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
IDO1 P14902 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10961790 0.85 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2KDM4EKMT2ANPC1
SCHEMBL10960207 0.84 KDM4E (0.49) ALDH1A1SMN1; SMN2KDM4EKMT2ALMNA
SCHEMBL2201365 0.83 CACNA1F (0.47) ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL2202109 0.78 GRM5 (0.48) ALDH1A1SMN1; SMN2KDM4EKMT2ANPC1
SCHEMBL10958975 0.76 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2KDM4ERAB9ALMNA
SCHEMBL10960761 0.74 LMNA (0.41) ALDH1A1SMN1; SMN2KMT2ALMNAHTT
SCHEMBL27676266 0.74 CYP1A2 (0.45) ALDH1A1SMN1; SMN2KDM4EKMT2ANPC1
SCHEMBL31617413 0.74 NPC1 (0.42) ALDH1A1SMN1; SMN2KDM4EKMT2ANPC1
SCHEMBL2200016 0.73 JAK1 (0.41) ALDH1A1KMT2APLAUMEN1
SCHEMBL10960527 0.72 LMNA (0.52) ALDH1A1SMN1; SMN2KDM4EKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
CN-101765430-A Novel pyrazole derivatives HOFFMANN LA ROCHE 2010-06-30 CN disclosed
EP-2182953-A2 NEW PYRAZOL DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-05-12 EP disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed
WO-2009013211-A2 NEW PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029963-A1 PYRAZOL DERIVATIVES CCR1, CCR3, CCRL2 ALDH1A1 1476/4885SMN1; SMN2 4368/4885KDM4E 3694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.